POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced its expansion into Germany as POA Pharma GmbH.

POA Pharma, headquartered in Copenhagen with additional facilities located across the Nordic region, is part of Galen Limited.  This privately owned company, which was established in 1968, has global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, continental Europe, and the USA.

POA Pharma currently represents 12 partners from nine countries and includes a portfolio of products across a number of therapeutic areas, including Acute Care (anaesthesiology/emergency medicine), Otolaryngology (ENT) and Medical Nutrition.

The POA Pharma GmbH team, headed by Dr Dennise Broderick, President of Galen, and Managing Directors Rens Reinhoudt and Ton Alblas, has extensive expertise in supporting partners, healthcare professionals and patients within Europe.

As part of a multinational company, POA Pharma GmbH has substantial infrastructure and support services at its disposal, providing the strategy and resources to deliver the company’s ambitious growth plans.

POA Pharma GmbH will focus on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease medication bringing German patients selected products and services of POA Pharma Scandinavia AB.

Dr Dennise Broderick said: “POA Pharma is part of the wider Galen family, and we are committed to doing all we can to improve the lives and benefit the health of all generations affected by a variety of diseases.

This expansion is highly complementary to our established business and marks a key milestone in our strategic global growth plans.

“At POA Pharma, our purpose is to be of extraordinary service to our patients, healthcare professionals and partners and we are thrilled to now offer our services in Germany.”

Over the course of 2023, POA Pharma GmbH, will be introducing its first medical food products into Germany, for patients with metabolic diseases such as Phenylketonuria (PKU).

To celebrate this launch in 2023, POA Pharma will also support a Medical Nutrition Scholarship Award for the IMD Community, with two successful applicants from the German IMD community each being awarded a bursary of up to €2,500 towards their education or training course support and a technology package.

The POA Pharma GmbH team will be attending the German PKU members conference on 21^st – 23^rd April in Schmitten and are looking forward to their first interaction with patients.

To get in touch or find out more about POA Pharma’s German activities, visit: www.poapharma.de